Pancreatic Cancer Research

ResearcherHokkaido UniversityActive in the last 2 years

Hideki Ueno

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4150-9500; OpenAlex author ID A5116130529. Sources: OpenAlex.

Their work

Papers
16 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
58
Papers, trials and grants by year

2011: 1 paper · 2012: 3 papers · 2013: none · 2014: none · 2015: 1 paper · 2016: 1 paper · 2017: 4 papers · 2018: none · 2019: 1 paper · 2020: none · 2021: none · 2022: 2 papers · 2023: 2 papers · 2024: 1 paper

Papers 16

  1. Study Protocol for a Prospective Self-Controlled Trial on Success in Meeting Comprehensive Genomic Profiling Analysis Criteria for Specimens Obtained by Endosc… Co-author DOI 10.3390/diseases12080182↗
  2. Clinical features of germline BRCA1/2 or ATM pathogenic variant positive pancreatic cancer in Japan. Co-author DOI 10.1016/j.pan.2023.10.017↗
  3. Fine-needle biopsy with 19G needle is effective in combination with endoscopic ultrasound-guided tissue acquisition for genomic profiling of unresectable pancr… Co-author DOI 10.1111/den.14423↗
  4. Proportion of unresectable pancreatic cancer specimens obtained by endoscopic ultrasound-guided tissue acquisition meeting the OncoGuide™ NCC Oncopanel System … Co-author DOI 10.1007/s00535-022-01926-z↗
  5. Safety and efficacy of S-IROX (S-1, irinotecan and oxaliplatin combination therapy) in patients with advanced pancreatic cancer: A multicenter phase 1b dose-es… First author DOI 10.1016/j.ejca.2022.06.010↗
  6. Impact of the Duration of Diabetes Mellitus on the Outcome of Metastatic Pancreatic Cancer Treated with Gemcitabine: A Retrospective Study. Co-author DOI 10.2169/internalmedicine.2539-18↗
  7. Phase 1b study of galunisertib in combination with gemcitabine in Japanese patients with metastatic or locally advanced pancreatic cancer. Last author DOI 10.1007/s00280-017-3313-x↗
  8. Updated results from GEST study: a randomized, three-arm phase III study for advanced pancreatic cancer. Co-author DOI 10.1007/s00432-017-2349-y↗
  9. Utility of Assessing the Number of Mutated KRAS, CDKN2A, TP53, and SMAD4 Genes Using a Targeted Deep Sequencing Assay as a Prognostic Biomarker for Pancreatic … Co-author DOI 10.1097/mpa.0000000000000760↗
  10. An Oncogenic ALK Fusion and an RRAS Mutation in KRAS Mutation-Negative Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1634/theoncologist.2016-0194↗
  11. C-Reactive Protein Level Is an Indicator of the Aggressiveness of Advanced Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000000465↗
  12. [Adverse event and countermeasure with regard to FOLFIRINOX for pancreatic cancer]. First author PMID 25831830↗
  13. Phase I/II study of gemcitabine as a fixed dose rate infusion and S-1 combination therapy (FGS) in gemcitabine-refractory pancreatic cancer patients. Co-author DOI 10.1007/s00280-011-1786-6↗
  14. Treatment outcome for systemic chemotherapy for recurrent pancreatic cancer after postoperative adjuvant chemotherapy. Co-author DOI 10.1016/j.pan.2012.07.016↗
  15. Salvage chemoradiotherapy after primary chemotherapy for locally advanced pancreatic cancer: a single-institution retrospective analysis. Co-author DOI 10.1186/1471-2407-12-609↗
  16. Construction and validation of a prognostic index for patients with metastatic pancreatic adenocarcinoma. Co-author DOI 10.1097/mpa.0b013e3182021376↗

Closest collaborators

The 25 strongest of 58 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Takuji Okusaka · 15 shared papers, 2011–2024 · strength 1.17
  2. Chigusa Morizane · 14 shared papers, 2011–2024 · strength 1.12
  3. Susumu Hijioka · 4 shared papers, 2022–2024 · strength 0.57
  4. Akihiro Ohba · 4 shared papers, 2022–2023 · strength 0.54
  5. Masafumi Ikeda · 7 shared papers, 2011–2022 · strength 0.41
  6. Hidetoshi Kitamura · 3 shared papers, 2022–2023 · strength 0.41
  7. Go Ikeda · 3 shared papers, 2022–2023 · strength 0.41
  8. Kotaro Takeshita · 3 shared papers, 2022–2024 · strength 0.41
  9. Yasushi Yatabe · 3 shared papers, 2022–2024 · strength 0.41
  10. Daiki Yamashige · 2 shared papers, 2023–2024 · strength 0.29
  11. Nobuyoshi Hiraoka · 3 shared papers, 2017–2023 · strength 0.24
  12. Yuya Hisada · 2 shared papers, 2022–2023 · strength 0.24
  13. Shota Harai · 2 shared papers, 2022–2023 · strength 0.24
  14. Shuichi Mitsunaga · 5 shared papers, 2011–2019 · strength 0.21
  15. Mitsuhito Sasaki · 2 shared papers, 2019–2022 · strength 0.21
  16. Hiroshi Imaoka · 2 shared papers, 2019–2022 · strength 0.21
  17. Junji Furuse · 3 shared papers, 2012–2022 · strength 0.20
  18. Shin Yagi · 1 shared paper, 2024 · strength 0.16
  19. Kazuaki Shimada · 3 shared papers, 2012–2017 · strength 0.14
  20. Naohiro Okano · 1 shared paper, 2022 · strength 0.13
  21. Masato Ozaka · 1 shared paper, 2022 · strength 0.13
  22. Fumio Nagashima · 1 shared paper, 2022 · strength 0.13
  23. Naoki Sasahira · 1 shared paper, 2022 · strength 0.13
  24. Katsuhiko Iwakiri · 1 shared paper, 2023 · strength 0.13
  25. Yoko Shimada · 2 shared papers, 2017 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.